Chimeric antigen receptor–modified T cells: CD19 and the road beyond

Slides:

Advertisements

Similar presentations

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):

Advertisements

Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience.

Uncontrolled Wnt signaling causes leukemia

The beauty of TLR agonists for CTCL

GVHD-associated immunodeficiency: soil or seed?

Do HSCs divide asymmetrically?

Adoptive Immunotherapy Following Umbilical Cord Blood Transplantation Using The Sleeping Beauty System and Artificial Antigen Presenting Cells To Generate.

by Dai Chida, Osamu Miura, Akihiko Yoshimura, and Atsushi Miyajima

TCR-MHC-peptide(s): in vivo veritas

“Vitamin hypothesis”: explanation for allergy increase?

Fledgling prognostic markers in CLL

Next-generation leukemia immunotherapy

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

by Zhenping Zhu Blood Volume 108(6): September 15, 2006

Glis: novel modulators of TCR signaling?

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.

Tax fingerprint in adult T-cell leukemia

Figure 1 Chimeric antigen receptor (CAR) structures

Mechanisms of HIV-associated lymphocyte apoptosis

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma by Chan Yoon Cheah, Loretta J. Nastoupil,

Fusion genes in cord blood

Engineering regulatory T cells against factor VIII inhibitors

Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?

CAR T cell therapy—principle and clinical trial overview

CAR T cell therapy—principle and clinical trial overview

Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care? Arjan C. Lankester, Franco Locatelli, Peter Bader, Eva Rettinger,

Figure 1 CAR-T-cell design

T cell receptor Vβ (TCR-Vβ) expression in a drug-specific T cell line (TCL) and specificity assay of a TCL of patient P1. T cell receptor Vβ (TCR-Vβ) expression.

Rare cells predict GVHD

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Lymphoma spread? Target CD47-SIRPα!

Gremlin: vexing VEGF receptor agonist

Daniel Abate-Daga, Marco L Davila Molecular Therapy - Oncolytics

Anergy: the CLL cell limbo

Chemokines and chemokine receptors: here, there, and everywhere

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Neuroblastoma and Ewing's Sarcoma Associated with ROR1 Expression Can Be Effectively Targeted with NK Cells Modified to Express an Anti ROR1 Chimeric.

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

Titratable control of engineered therapeutic T cells through an ON-switch chimeric antigen receptor. Titratable control of engineered therapeutic T cells.

Mechanism of CTLA-4-induced immunosuppression.

The Other Face of Chimeric Antigen Receptors

Volume 3, Issue 5, Pages (May 2003)

Schematic representation of mechanisms leading to the synergy of anti-CD137 and anti–PD-1 immunostimulatory mAbs. Schematic representation of mechanisms.

ROR1-Specific Chimeric Antigen Receptor (CAR) NK Cell Immunotherapy for High Risk Neuroblastomas and Sarcomas Haein Park, Aradhana Awasthi, Janet Ayello,

Franco Locatelli, Damiano Rondelli, G.Roberto Burgio

New Cell Sources for T Cell Engineering and Adoptive Immunotherapy

Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse Saad S. Kenderian, David L. Porter,

Chimeric antigen receptor T-cell therapy for solid tumors

by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A

Annika Berntsen, Poul F. Geertsen, Inge Marie Svane European Urology

Not Just Any T Cell Receptor Will Do

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Genetically modified TCRs for cancer immunotherapy.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Bigger, Stronger, Faster: Chimeric Antigen Receptor T Cells Are Olympic Killers by Paul J Neeson, Alexander James Davenport, Joseph A Trapani, Michael.

A schematic presentation of secreted, endocytic, and signaling pattern-recognition receptors. A schematic presentation of secreted, endocytic, and signaling.

Fig. 1 Engineered T cells: design of TCR versus CAR T cells.

Biology and treatment of Richter syndrome

B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase.

A binding relationship with thrombin

CAR T cell immunotherapy for human cancer

Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Gene editing in hemophilia: a “CRISPR” choice?

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor.

A schematic diagram showing the mechanism by which L5 triggers platelet activation and aggregation. A schematic diagram showing the mechanism by which.

Model of the change in receptor structure on engagement of the ligand IFN-γ. Model of the change in receptor structure on engagement of the ligand IFN-γ.

Presentation transcript:

Chimeric antigen receptor–modified T cells: CD19 and the road beyond by Alexander I. Salter, Margot J. Pont, and Stanley R. Riddell Blood Volume 131(24):2621-2629 June 14, 2018 ©2018 by American Society of Hematology

CAR design. CAR design. (A) Schematic of TCR and costimulatory molecule expression on T cells. (B-C) Synthetic single-chain receptors designed to deliver modified signal 1 and signal 2 in an scFv/CD28/CD3ζ (B) or scFv/4-1BB/CD3ζ format (C). Alexander I. Salter et al. Blood 2018;131:2621-2629 ©2018 by American Society of Hematology

CAR toolbox. CAR toolbox. Toolbox of applications in synthetic biology that may extend and enhance the efficacy and safety of ACT. Alexander I. Salter et al. Blood 2018;131:2621-2629 ©2018 by American Society of Hematology